6CM
ADMA icon

683 Capital Management’s ADMA Biologics ADMA Stock Holding History

683 Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$451K Hold
50,000
– – 0.02% 190
2025
Q4 		$912K Buy
+50,000
New +$843K 0.04% 148

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

683 Capital Management's ADMA Position: Q2 2022 in Review

683 Capital Management sold out of ADMA Biologics (ADMA) in Q2 2022, closing a stake of 222,603 shares — an estimated $407K sold.

683 Capital Management first reported a position in ADMA in Q4 2017 and held it in 15 quarters. The position peaked at $6.34M in Q3 2019. 113 funds tracked by Wall St. Rank hold ADMA as of Q2 2022.

  • 683 Capital Management reported no remaining ADMA Biologics position as of Q2 2022 after selling out during the quarter.
  • 683 Capital Management sold 222,603 ADMA Biologics shares in Q2 2022, an estimated $407K.
  • 683 Capital Management first reported a position in ADMA Biologics in Q4 2017 and held it in 15 quarters.
  • 683 Capital Management's ADMA Biologics position peaked at $6.34M in Q3 2019.
  • 113 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2022.

Based on 683 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.